Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

about

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Item

http://www.wikidata.org/entity/Q48267612

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@en

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@nl

type

Item

label

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@en

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@nl

prefLabel

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@en

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

@nl

P1476

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma

@en

P2093

B J Biller

http://www.w3.org/2001/XMLSchema#string

C A London

http://www.w3.org/2001/XMLSchema#string

D M Vail

http://www.w3.org/2001/XMLSchema#string

J Coy

http://www.w3.org/2001/XMLSchema#string

P2860

The efficacy of temozolomide for recurrent glioblastoma multiforme.

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.

Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.

Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.

P304

E23-E29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12328

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Douglas H Thamm

T Laver

P577

2017-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28621057

http://www.w3.org/2001/XMLSchema#string